News

Manufacturing Chemist | The increasing power of single-cell omics: changing the future of medicine

Advances in the single-cell genomic analysis of cells and tissues, including the required computational methods, have now put systematic, high-resolution and comprehensive reference maps of all human cells within our reach. Paradigm4’s Marilyn Matz, CEO and cofounder, and Dr Zachary Pitluk, VP of Life Sciences and Healthcare, report

whitepages icon x

World Pharma Today || Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.

whitepages icon x

54gene Enlists Paradigm4’s Science-Ready Data Solution for its African Health Information Ecosystem

12 JANUARY 2021: Paradigm4, specialist in scientific data management and scalable computation, has signed an agreement with 54gene, a health technology company deriving insights from the world’s most diverse populations to solve some of healthcare’s biggest challenges. The agreement will allow 54gene to use Paradigm4’s REVEALTM Biobank app to explore,

whitepages icon x

Pharma’s Almanac | Enabling Pharma Researchers to Think Differently with Effective Data Manipulation

Pharma researchers are tasked with organizing disparate data, which detracts from time spent understanding disease mechanisms and enabling the development of more effective drugs. Paradigm4 is tackling this issue with a new platform based on a novel approach to data organization and elastic computing. Even companies with small budgets can